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Sang Yup Lee1, Diethard Mattanovich2,3 and Antonio Villaverde4,5,6*Cell factories have been largely exploited for the con-
trolled production of substances of interest for food,
pharma and biotech industries. Although human-con-
trolled microbial production and transformation are
much older, the cell factory concept was fully established
in the 80’s through the intensive public and private in-
vestment. Strongly empowered by the then nascent re-
combinant DNA technologies and supported by the
approval of recombinant insulin [1,2], the principle of
controlled biological production as a convenient source
of difficult-to-obtain molecules (especially those of high
added value) deeply penetrated the industrial tissue,
soon becoming a widespread platform aiming at cost-
effective large-scale production [3]. The first generation
cell factories (mainly composed by plain strains of the
bacterium Escherichia coli and the yeast Saccharomyces
cerevisae) were soon replaced by engineered variants.
Resulting from the application of untargeted mutagen-
esis and phenotypic selection, conventional genetic
modification, metabolic engineering, and more recently
by systems metabolic engineering that integrates meta-
bolic engineering with systems biology and synthetic
biology, new strains having much enhanced performance
have been progressively developed [4-19]. In parallel,
mammalian and insect cells for the production of high
quality proteins, and other microbial species appealing
from an industrial point of view due to their unusual
physiological traits, have been incorporated to the cell
factory family [20,21]. This comprises algae, fungi, psy-
chrophilic bacteria and moss, among others [22-26]. On
the other hand, a set of food-grade lactic acid bacteria
are under development as emerging platforms in food
microbiology but also as a novel source of metabolites
and proteins [27-34]. The physiological diversity of the
microbial world offers an intricacy of biosynthetic* Correspondence: antoni.villaverde@uab.cat
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reproduction in any medium, provided the orpathways from which novel bio-products, including
nano- or micro-structured materials [35-37], offer pro-
mises in even more diverse applications.
Still, many substances and materials of industrial inter-
est are nowadays produced by chemical synthesis, and
the number of (recombinant) proteins approved for
therapeutic use hardly reaches 200, a figure much lower
than that initially presumed. However, both environmen-
tal concerns and medical and industrial needs strongly
push towards a fully sustainable bio-production of a lar-
ger spectrum of substances. Then, how much limited is
the economic feasibility of microbial production? Have
the cell factories reached a plateau in their development?
Is there more room for further exploitation of the mi-
crobial production?
Systems metabolic engineering [38,39] offers a set of
methodological and strategic tools for the design and
optimization of metabolic and gene regulatory networks
for the efficient production of chemicals (from pharma-
ceuticals to bulk chemicals and fuels) and materials
(from plastics to high value materials) [5-7,40]. Further-
more, creation of new metabolic pathways and fine tun-
ing of the existing ones have become possible [8,15].
This is already allowing the production of substances so
far reluctant to microbial production under industrial
requirements and under cost-effective processes, allow-
ing us to overcome limitations of microbial cell factories.
In silico genome-scale metabolic modeling and simula-
tion are playing increasingly important roles in system-
wide identification of target genes and pathways to be
manipulated to enhance production of desired products.
Profiling of transcriptome, proteome, metabolome, and/
or fluxome is also becoming a routine practice in meta-
bolic engineering for the better understanding of cellular
characteristics under given genetic and/or environmental
perturbations. Through the system-wide optimized de-
sign and development of microbial cell factories, many
industrially important chemicals and materials could be
efficiently produced. Some example products include,
but not limited to, alcohols other than ethanol including. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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such as succinic acid, fumaric acid, malic acid and
adipic acid, diols such as 1,3-propanediol, 1,2-propane-
diol, 1,4-butanediol and 2,3-butanediol, diamines such
as putrescine and cadaverine, and even polymers includ-
ing polyhydroxyalkanoates, polylactic acid, spider silk
protein, poly-gamma-glutamic acid, and many others
[40]. It is expected that increasingly diverse chemicals
and materials that are currently produced by petrochem-
ical industry will be produced by employing microbial
cell factories.
Improving cell factories by systems biotechnology to
an industrially relevant level cannot be successfully
reached by individual teams alone. A wide range of
expertise is needed for the full development of a novel
biotechnological process, including microbiology, chem-
istry, bioinformatics, biochemical engineering, but also
agricultural and plant sciences and economics. After a
proof of concept has shown the feasibility of a novel
approach for cell factory engineering, large consortia or
networks of fully skilled teams should take over in col-
laboration with Biotech companies to accomplish an
economically feasible bioprocess. As an early example,
the development of bacteria producing 1,3-propanediol
from glucose has been well documented, and required
the engineering of more than 70 genes, before process
development and scale up were reasonably made [41].
Replacing materials which are produced from mineral
oil by biobased products requires not only efficient
technology but also the assessment of economical and
ecological feasibility, as intensely studied for polylactic
acid [42].
As the progress of industrial biotechnology did not
accomplish the desired speed of development [43] aca-
demic researchers have teamed up with industry in pub-
licly funded research centers worldwide. To name a
few, the Joint BioEnergy Institute (JBEI) in the San
Francisco Bay Area, the Novo Nordisk Foundation
Center for Biosustainability (CFB) at the Technical Uni-
versity of Denmark, the Metabolic and Biomolecular
Engineering Laboratory (MBEL) of the Korea Advanced
Institute of Science and Technology (KAIST), the Dutch
Klyuver Centre for Genomics of Industrial Fermentation,
or the Austrian Centre of Industrial Biotechnology
(ACIB) share the mission to speed up development of
industrial bioprocesses by joining forces of different aca-
demic disciplines with industrial collaborators.
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